公开(公告)号：US20180185517A1

公开(公告)日：2018-07-05

申请号：US15899326

申请日：2018-02-19

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K48/00 ,  C12N15/63 ,  C07K14/505 ,  C07K16/32 ,  C12N15/67 ,  C12N15/85

CPC classification number: A61K48/0066 ,  A61K39/00 ,  A61K48/00 ,  C07K14/505 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/50 ,  C12N2840/105

Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

公开(公告)号：US20180169218A1

公开(公告)日：2018-06-21

申请号：US15892330

申请日：2018-02-08

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K39/145 ,  C12N7/00

Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

公开(公告)号：US20170056529A1

公开(公告)日：2017-03-02

申请号：US15233933

申请日：2016-08-10

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C07K14/505 ,  C07K16/32

CPC classification number: A61K48/0066 ,  A61K39/00 ,  A61K48/00 ,  C07K14/505 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/50 ,  C12N2840/105

Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

Abstract translation: 本发明涉及包含或编码编码区的核酸序列，其编码至少一种包含治疗性蛋白质或其片段，变体或衍生物的肽或蛋白质，至少一种组蛋白茎环和聚（A ）序列或聚腺苷酸化信号。 此外，本发明提供了用于增加所述编码的肽或蛋白质的表达的核酸的用途，特别是用于基因治疗。 它还公开了其用于制备药物组合物的用途，例如 用于基因治疗，特别是用于治疗需要用治疗性肽或蛋白质治疗的疾病，优选如本文所定义。 本发明还描述了使用包含或编码组蛋白茎环和聚（A）序列的核酸或增加包含治疗性蛋白或其片段，变体或衍生物的肽或蛋白质的表达的方法， 多聚腺苷酸化信号。

公开(公告)号：US20160206756A1

公开(公告)日：2016-07-21

申请号：US14945349

申请日：2015-11-18

Applicant: CUREVAC AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K48/00 ,  A61K39/00

CPC classification number: A61K48/0066 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/575 ,  C07K14/435 ,  C12N15/67

Abstract: The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.

公开(公告)号：US20240102065A1

公开(公告)日：2024-03-28

申请号：US18262912

申请日：2022-01-26

Applicant: CUREVAC AG

Inventor： Moritz THRAN ,  Andreas THESS ,  Fabian EBER ,  Dipankar BHANDARI

IPC: C12P19/34 ,  A61K39/015 ,  A61K39/205 ,  A61K48/00 ,  A61P37/04 ,  C07K16/10

CPC classification number: C12P19/34 ,  A61K39/015 ,  A61K39/205 ,  A61K48/005 ,  A61P37/04 ,  C07K16/10 ,  A61K2039/575 ,  C12N2760/20122

Abstract: The present invention provides a method of reducing the immunostimulatory properties of an in vitro transcribed RNA by producing the in vitro transcribed RNA comprising a 3′ terminal A nucleotide. Hereby, the circular DNA template used to generate the in vitro transcribed RNA has been linearized using a type IIS endonuclease. The invention further provides pharmaceutical compositions comprising the vitro transcribed RNA comprising a 3′ terminal A nucleotide according to the invention for use in therapy.

公开(公告)号：US20200332293A1

公开(公告)日：2020-10-22

申请号：US16920701

申请日：2020-07-04

Applicant: CureVac AG

Inventor： Andreas THESS

IPC: C12N15/113 ,  C12N15/67 ,  C12N15/85 ,  A61K39/00 ,  A61K48/00

Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a polyadenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.

公开(公告)号：US20200276336A1

公开(公告)日：2020-09-03

申请号：US16848991

申请日：2020-04-15

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K48/00 ,  C12N15/67 ,  C07K14/435 ,  A61K39/00

Abstract: The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.

公开(公告)号：US20180161422A1

公开(公告)日：2018-06-14

申请号：US15892356

申请日：2018-02-08

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K39/145 ,  C12N7/00

Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

公开(公告)号：US20180044687A1

公开(公告)日：2018-02-15

申请号：US15534496

申请日：2015-12-11

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Stefanie GRUND

IPC: C12N15/67 ,  C12N15/85 ,  C12N15/68 ,  A61K39/145 ,  A61K39/205

CPC classification number: C12N15/67 ,  A61K39/12 ,  A61K39/145 ,  A61K39/205 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/575 ,  C12N15/68 ,  C12N15/85 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2760/20134 ,  C12N2760/20171 ,  C12N2830/50

Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

公开(公告)号：US20170196967A1

公开(公告)日：2017-07-13

申请号：US15465322

申请日：2017-03-21

Applicant: CureVac AG

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K39/145 ,  C12N7/00

CPC classification number: A61K39/145 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/64 ,  C12N7/00 ,  C12N15/63 ,  C12N15/67 ,  C12N2760/16134 ,  C12N2830/50 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/397 ,  Y02A50/403 ,  Y02A50/412 ,  Y02A50/414 ,  Y02A50/416 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/476 ,  Y02A50/487

Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.